Press Releases

New Program Expands Access to PacBio's Highly Accurate Sequencing Systems by Providing Flexible Financing   MENLO PARK, Calif. , Sept. 12, 2023 /PRNewswire/ -- PacBio  (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PacBio Capital , a

Hamilton, Integra, Revvity, and Tecan Join PacBio Compatible to Offer Verified Automated Library Prep Workflows for Whole Genome Sequencing MENLO PARK, Calif. , Sept. 7, 2023 /PRNewswire/ -- PacBio  (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today

MENLO PARK, Calif. , Aug. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:     UBS MedTech, Tools and Genomics Summit 2023

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms  MENLO PARK, Calif. and STAMFORD, Conn. , Aug. 7, 2023 /PRNewswire/ -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions and GeneDx (Nasdaq: WGS), a

MENLO PARK, Calif. , Aug. 4, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that PacBio's Compensation Committee of the  Board of Directors granted non-qualified stock options covering an aggregate of 100,000

MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2023 .     Second quarter  results Revenue of $47.6 million , a 34% increase compared with $35.5 million in the prior year-period.

PacBio will Combine Apton's Proprietary Sequencing Technology With its Highly Accurate Sequencing by Binding Chemistry to Develop a High-Throughput Sequencer Designed to Deliver Billions of Reads per Flow Cell MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio, a leading developer of

The Onso Platform Delivers Extraordinary Accuracy Which Creates New Possibilities for Research and Translational Sequencing Applications MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio  (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced

MENLO PARK, Calif. , July 19, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023 , at 5:00 pm Eastern Time .     The call will be webcast and may be accessed at

Bioscientia Acquires Multiple Revio Sequencing Systems to Revolutionize Rare Disease Research by Sequencing Thousands of Long-Read Human Genomes Annually MENLO PARK, Calif. , June 28, 2023 /PRNewswire/ --  PacBio , a leading developer of high-quality, highly accurate sequencing solutions, today